Malignant pleural mesothelioma is a highly aggressive tumor associated with asbestos exposure. There are few effective treatment options for mesothelioma, and patients have a very poor prognosis with a median survival of < 12 months from diagnosis. Biomarkers have been 
Malignant pleural mesothelioma is a highly aggressive tumor commonly associated with asbestos exposure. There are > 15,000 cases worldwide, and there is real concern that unregulated asbestos use in Asia will see the number of cases significantly increase. 1 Clinical management of mesothelioma for most patients is largely palliative and based on combination cisplatin and pemetrexed chemotherapy. Recent randomized trial results suggest that bevacizumab may be considered an alternative first-line treatment option, but as yet this not been routinely clinically adopted. 2 A selective subset of patients with good performance indicators may undergo cytoreductive procedures with curative intent as part of a multimodality approach with chemotherapy and radiotherapy; however, debulking pleurectomy is sometimes performed with palliative intent for symptom control. 2 New therapies are currently being actively explored for this cancer, including immunotherapeutic approaches.
Biomarkers have been proposed as a cost-effective means of cancer management, and the search for a mesothelioma biomarker has been ongoing for the last 30 years. In an appropriate clinical setting, tumor biomarkers can play a meaningful role in diagnosis, prognosis, predicting treatment responses, monitoring response, and screening for the early detection of disease. Many traditional, soluble (glycol-)protein biomarkers have been evaluated in mesothelioma over this time, mostly in a case-control setting as diagnostic or screening markers. More recently, through highthroughput biomarker discovery programs, an everincreasing list of new biomarkers, including messenger RNA, DNA, microRNA, and antibody targets, are being proposed for mesothelioma. This list in general requires further follow-up studies. In the current review we will focus on the discovery and clinical usages of soluble mesothelin, which is one of the few blood-based biomarkers to receive US Food and Drug Administration (FDA) approval for clinical use in cancer. 3 With the advent of targeted therapy, based on a patient's individual tumor characteristics, and the rapid progress in immunotherapy for mesothelioma treatment, there will be a requirement to extend biomarker discovery and validation in the future to an individualized approach to assess a patient's suitability to these treatments.
Discovery of Mesothelin
Mesothelin was identified as an antigen on the surface of ovarian cancer cells through an elegant series of experiments in the early 1990s. 4 The mesothelin gene, MSLN, encodes a precursor protein that is subsequently processed into two proteins, mesothelin and megakaryocyte potentiating factor (MPF). Mesothelin is an approximately 40-kDa glycoprotein that is attached to the cell surface by a glycosylphosphatidylinositol anchor and is expressed on mesothelioma, ovarian, pancreatic, and other cancers, with limited expression on normal tissues. Regulation of mesothelin expression is not fully understood; however, a role for the wnt/ b-catenin pathway has been suggested, 5 and promoter methylation has been demonstrated to be one means of controlling expression. 6 In some situations, mesothelin can be shed from the cell surface through the actions of tumor necrosis factor-a-converting enzyme and can be detected in the blood. 4 
Mesothelin as a Biomarker for Malignant Mesothelioma
In 1999, the Hellstrom Laboratory reported elevated levels of a soluble serum mesothelin-related protein in 23 of 30 patients with ovarian cancer using a double determinant enzyme-linked immunosorbent assay they had developed with antibodies directed against ovarian cancer antigens. 7 Because mesothelioma is a mesothelinpositive tumor, we performed a collaborative study with them and found that 37 out of 44 (87%) patients with mesothelioma also had significantly elevated levels of this protein in the serum compared with apparently healthy asbestos-exposed subjects, non-asbestos-exposed control subjects, and clinically relevant control subjects. 8 Subsequent case-control studies from many centers around the world have confirmed that mesothelin is preferentially elevated in the serum of patients with mesothelioma with high specificity for mesothelioma. 9 The assay to quantitate soluble mesothelin was commercialized by Fujirebio Diagnostics and marketed under the name MESOMARK. In 2007, the MESOMARK assay was approved as a humanitarian use device by the US FDA 10 for the monitoring of epithelioid and biphasic mesothelioma using serum as an analyte. The assay was also approved or licensed for use in this setting in many other countries, including Australia.
Diagnostics
None of the FDA-approved circulating protein cancer biomarkers are recommended in practice guidelines for cancer diagnosis. 11 However, some are used as diagnostic aids in symptomatic individuals whereby an elevated level increases the level of suspicion of disease and the need for invasive tissue acquisition steps at an earlier time than otherwise indicated. Prostate-specific antigen, for instance, is a well-known biomarker for prostate cancer; however, considerable controversy surrounds its use. Prostate-specific antigen can be elevated in individuals with benign prostate enlargement and prostate inflammation and thus lacks specificity for the malignant condition, which has been reported to lead to unnecessary biopsies or other invasive procedures. 12, 13 This is not the case for mesothelin, which exhibits a high level of specificity relative to benign pleural and pulmonary conditions 8 ; however, renal impairment has been shown to elevate serum mesothelin in the absence of malignancy.
14 Thus, in the absence of renal disease, an elevated mesothelin finding raises the suspicion of malignancy.
Elevated pleural fluid levels of mesothelin can also be useful in the clinical setting of an individual who is at risk of mesothelioma who presents with a pleural effusion. Elevated soluble mesothelin is more sensitive when measured in the effusion, rather than the serum. In several studies on consecutive series of patients presenting with pleural effusions being investigated for malignancy by cytologic examination, it was shown that effusion mesothelin could be clinically useful. [15] [16] [17] [18] In the context of an effusion being reported as being suspicious of malignancy, atypical, nonmalignant, or nondiagnostic, elevated mesothelin had a positive predictive value of > 57% (Table 1) , which should prompt further clinical investigation of the patient rather than observation alone. Curiously, effusion mesothelin appears to have specificity for malignancy in general, rarely being positive in benign conditions. This is not the case for other markers, such as cancer antigen 125, which has previously been proposed as a marker for effusions. Thus, effusion mesothelin has a clinical management role in patients with pleural effusion where malignancy is one of the differential diagnoses.
Approximately 10% of mesothelioma cases can occur in the peritoneal cavity, and such cases are frequently associated with production of serous effusion. To date, only a limited number of studies have examined biomarkers in malignant peritoneal mesothelioma, and most of these have consisted of a small number of peritoneal cases within a larger cohort of pleural cases. From the limited data available, it appears that elevated mesothelin concentrations in ascites of patients with mesothelioma are also indicative of malignancy. 19 
Monitoring
Most FDA-approved circulating cancer biomarkers are used for monitoring therapeutic response to treatment, particularly for early detection of relapse so that a new treatment strategy can be pursued. Several studies have indicated that mesothelin is useful as a monitoring biomarker. Various treatments have resulted in a decrease in serum mesothelin levels that was associated with treatment response, tumor shrinkage, or survival (Table 2) . [20] [21] [22] [23] [24] [25] [26] Our own study found that, in addition to treatment-related reduction in mesothelin levels being predictive of survival, a greater number of patients could be evaluated using the biomarker than could be evaluated by radiologic methods. 22 Unfortunately, clinical utility is not universal because even with advanced stage disease, there are patients with mesothelioma in whom serum mesothelin is not detectable. The clinical reality of mesothelioma's progression and the limited treatment options available have meant that mesothelin has not been widely adopted as a monitoring tool, with clinicians relying primarily on imaging, such as CT scan and PET 15 Hooper et al, 16 and Creaney et al, 18 used a 20-nM cutoff, whereas Canessa et al 17 used a 9.3 nM-cutoff.
chestjournal.org scan. However, the characteristic morphology of mesothelioma, which usually forms a rind surrounding the lung rather than having a classical spheroid shape, presents significant quantitative difficulties for tumor treatment response measurement. Furthermore, quantitating response to immunotherapies by imaging can be confounded by the infiltration of tumor by immune cells, which appears as pseudoprogression before effective tumor reduction can be observed. Clinical adoption of tumor biomarkers for mesothelioma, including mesothelin, warrants further study to extend their usefulness. For example, monitoring the response of mesothelioma to therapies and guiding therapeutic decisions, including identification of ineffective toxic therapies much earlier and identification of effective therapies, warrant further study.
Screening
Great interest in biomarker research centers on their potential use in screening for the early detection of cancer. In principal, mesothelioma is a cancer that is amenable to early screening for a number of reasons. First, high-risk individuals can be readily identified as a result of their level of asbestos exposure, and individuals prospective studies have shown that monitoring serum mesothelin levels in asbestos exposed cohorts shows false-positive rates > 90% and thus does not assist in the early detection of mesothelioma. 28 The combination of a low sensitivity and low pretest probability is likely to result in a falsely high positive rate, [29] [30] [31] [32] [33] with associated unnecessary procedures and subjective anxiety, as previously seen when CA125 was used alone in screening for ovarian cancer. 34 Recently, we examined mesothelioma-specific isoforms of ENOX2 as screening biomarkers for mesothelioma. In a retrospective analysis, ENOX2 isoforms were detected in the serum of asbestos-exposed individuals 4 to 10 years prior to clinical diagnosis of mesothelioma. 35 This is an exciting preliminary finding that, in common with all new potential biomarkers at the discovery stage, requires extensive validation. If the potential of ENOX2 as an early mesothelioma biomarker is realized and a suitable high-throughput screening assay becomes available, the ability to diagnose mesothelioma before clinical symptoms are present in at-risk individuals will be realized. This will have the potential to increase the efficacy of the treatment options for mesothelioma that are available, or may become available, in the future.
Treatment
The limited expression of mesothelin on normal tissues has provided the impetus to test mesothelin as a target for immune-based therapies in mesothelioma and other tumor types with high mesothelin expression, such as pancreatic and ovarian cancers. Several phase I clinical studies have been performed to determine safety and dose of the anti-mesothelin immunotoxin, SS1P, and also of a chimeric antimesothelin antibody construct, MORAb-009 (amatuximab). 4 Issues arose with both strategies with patients developing anti-SS1P or antiMORAb-009 neutralizing antibodies that may have limited efficacy. Currently, strategies are being trialed to mitigate these autoantibody responses.
The efficacy of several other mesothelin-directed treatment approaches are being investigated, including of mesothelin antibody-drug conjugates (anetumab ravtansine), vaccines, and chimeric antigen receptors. 4 Anetumab ravtansine consists of a human antimesothelin antibody coupled to a microtubuletargeting esterified maytansinol (DM4); in preclinical studies, efficacy has been demonstrated in patients with mesothelioma-, pancreatic cancer-, and ovarian cancerderived xenografts. 36 A phase II trial is underway comparing anetumab ravtansine with vinorelbine in a second line setting in patients with mesothelioma. A live-attenuated strain of Listeria species, which expresses human mesothelin, has been developed as a vaccine. So far, minimal toxicity has been reported, 37 
Other Biomarkers
Hyaluronic acid has been shown in studies going back to the 1980s to be elevated in mesothelioma-associated pleural effusions. 40 The technical expertise previously required to measure hyaluronic acid by highperformance liquid chromatography may have limited the number of follow-up studies into this biomarker. However, studies using a more user-friendly assay system have shown that mesothelin and hyaluronic acid levels in effusion have similar diagnostic accuracy 41 and that by combining the two markers in a two-step model diagnostic accuracy can be improved. 42 Guidelines for cytologic diagnosis of mesothelioma recommend the use of ancillary tests in addition to traditional morphology analysis, which may include hyaluronic acid and mesothelin effusion biomarkers. 43 MPF, the N-terminal fragment of the mesothelin gene product (also referred to as N-ERC/mesothelin) appears to have a similar profile of expression to mesothelin. Several studies have reported similar diagnostic accuracy and monitoring results with the two markers. 23, 44 However, it is unlikely from a commercial point of view chestjournal.org that, with the presently available data, MPF would be pursued as a clinical biomarker for mesothelioma.
Various other potential biomarkers have been reported for mesothelioma, some with very high reported diagnostic accuracy, including a 13-component aptamer panel, 45 fibulin-3, 46 and an autoantibody biomarker panel. 47 Unfortunately, the high diagnostic accuracy of fibulin-3 has not been subsequently validated in independent studies, 48 and independent validation studies for the aptamer and autoantibody panel have not been reported. Other studies have explored the use of biomarker panels, particularly combining different markers with mesothelin as a means of improving disease predictive power in a diagnostic setting. One promising study found combining mesothelin with mir103a-3p increases diagnostic performance, and the authors suggest that this improvement may be in part because of the combination of different molecular classes of biomarkers. 49 Several studies have evaluated the clinical utility of osteopontin as a mesothelioma biomarker. Osteopontin lacks the specificity to be a diagnostic aid, but levels may reflect inflammatory and wound healing status. Indeed several studies have shown that osteopontin levels have prognostic and/or predictive value, but as yet this work has not seen significant clinical translation.
These and other reported biomarkers offer promise for future mesothelioma screening, diagnosis, and monitoring; however, further investigations are needed to support the original findings and demonstrate clinical utility.
Conclusions
Mesothelin remains one of the most promising biomarkers for malignant mesothelioma diagnosis and monitoring; however, low sensitivity limits its utility as a screening tool. If results from clinical trials targeting tumors expressing mesothelin bear fruit, then the promise, in terms of the sought after precision medicine goal, of having a diagnostic test to guide therapy could be soon realized. New biomarkers for mesothelioma are being actively investigated, but without validation studies clinical adoption is unlikely in the near future.
Many new mesothelioma biomarker candidates that are reported are not evaluated beyond the discovery phase; therefore, the potential of these biomarkers as diagnostic or monitoring tools remains unfulfilled. However, the promise of new therapeutic approaches that could significantly improve treatment outcomes for mesothelioma may spur a resurgence of interest in the use of biomarkers in this disease.
